Table 1 Study cohort characteristics
From: Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection
All subjects (n = 156) | Low-gene counts (n = 103) | High-gene counts (n = 53) | p Value | ||
|---|---|---|---|---|---|
Age, years, median (IQR) | 43 (35; 51) | 46 (36; 53) | 38 (35; 46) | 0.024 | |
Gender, n (%) | Men | 124 (79.5%) | 77 (74.8%) | 47 (88.7%) | 0.058 |
Women | 31 (19.9%) | 26 (25.2%) | 5 (9.4%) | 0.020 | |
Transgender women | 1 (0.6%) | 0 | 1 (1.9%) | 0.340 | |
Ethnicity, n (%) | Asiatic | 1 (0.6%) | 0 | 1 (1.9%) | 0.340 |
Caucasian | 124 (79.5%) | 88 (85.4%) | 36 (67.9%) | 0.013 | |
Hispanic-latin | 28 (17.9%) | 12 (11.7%) | 16 (30.2%) | 0.007 | |
Other | 3 (1.9%) | 3 (2.9%) | 0 | 0.551 | |
HIV-1 risk group, n (%) | MSM | 100 (64.1%) | 54 (52.4%) | 46 (86.8%) | <0.001 |
Non-MSM | 56 (35.9%) | 49 (47.6%) | 7 (13.2%) | ||
HIV-1 status, n (%) | HIV-1-negative | 27 (17.3%) | 11 (10.7%) | 16 (30.2%) | 0.004 |
HIV-1-positive | 129 (82.7%) | 92 (89.3%) | 37 (69.8%) | ||
HIV-1 phenotype, n (%) | Late presenter | 11 (7.1%) | 9 (8.7%) | 2 (3.8%) | 0.335 |
Discordant | 18 (11.5%) | 15 (14.6%) | 3 (5.7%) | 0.118 | |
Concordant | 53 (34.0%) | 42 (40.8%) | 11 (20.8%) | 0.277 | |
Early-treated | 13 (8.3%) | 8 (7.8%) | 5 (9.4%) | 0.277 | |
ART-naive | 15 (9.6%) | 8 (7.8%) | 7 (13.2%) | 0.783 | |
Viremic controller | 11 (7.1%) | 5 (4.9%) | 6 (11.3%) | 0.033 | |
Elite controller | 8 (5.1%) | 5 (4.9%) | 3 (5.7%) | 0.421 | |
HIV-1-negative | 27 (17.3%) | 11 (10.7%) | 16 (30.2%) | 0.004 | |
BMI, kg/m2, median (IQR) | 23.8 (22.0; 26.1) | 23.7 (21.8; 25.5) | 24.4 (22.3; 26.3) | 0.215 | |
History of allergy, n (%) | Yes | 30 (19.2%) | 21 (20.4%) | 9 (17.0%) | 0.673 |
No | 122 (78.2%) | 78 (75.7%) | 44 (83.2%) | 0.413 | |
NA | 4 (2.6%) | 4 (3.9%) | 0 | 0.300 | |
Antibiotic intake, previous 3 months, n (%) | Yes | 2 (1.3%) | 2 (1.9%) | 0 | 0.549 |
No | 154 (98.7%) | 101 (98.1%) | 53 (100.0%) | ||
Antibiotic intake, previous 6 months, n (%) | Yes | 35 (22.4%) | 26 (25.2%) | 9 (17.0%) | 0.312 |
No | 121 (77.6%) | 77 (74.8%) | 44 (83.0%) | ||
Fecal consistency, n (%) | Hard | 56 (35.9%) | 33 (32.0%) | 23 (43.4%) | 0.217 |
Soft | 91 (58.3%) | 63 (61.2%) | 28 (52.8%) | 0.392 | |
Liquid | 5 (3.2%) | 4 (3.9%) | 1 (1.9%) | 0.662 | |
NA | 4 (2.6%) | 3 (2.9%) | 1 (1.9%) | 1.000 | |
Abdominal transit alterations, n (%) | Yes | 23 (14.7%) | 14 (13.6%) | 9 (17.0%) | 0.636 |
No | 127 (81.4%) | 85 (82.5%) | 42 (79.2%) | 0.666 | |
NA | 6 (3.8%) | 4 (3.9%) | 2 (3.8%) | 1.000 | |
CD4+ T-cell counts, median (IQR) | Current, cells/mm3 | 700.0 (462.0; 860.0) | 635.5 (331.0; 851.2) | 750.0 (558.0; 930.0) | 0.126 |
Current, % | 33.0 (24.2; 40.2) | 32.8 (23.6; 40.2) | 33.8 (25.6; 40.3) | 0.474 | |
Nadir, cells/ mm3 | 337.0 (140.0; 528.5) | 280.0 (113.0; 491.5) | 443.0 (339.0; 601.0) | 0.002 | |
CD8+ T-cell counts, median (IQR) | Current, cells/ mm3 | 776.5 (576.0; 1012.0) | 791.5 (558.8; 991.2) | 748.5 (604.2; 1158.0) | 0.294 |
Current, % | 39.4 (33.0; 48.92) | 38.2 (31.6; 49.7) | 41.6 (34.9; 47.1) | 0.607 | |
CD4+/CD8+ ratio | 0.9 (0.5; 1.2) | 0.9 (0.5; 1.3) | 0.8 (0.5;1.2) | 0.943 | |
HIV-1 RNA, copies/mL, median (IQR) | <40.0 (40.0; 711.5) | <40.0 (40.0; 79.5) | <40.0 (40.0; 1339.0) | 0.074 | |
